SG10201406263SA - Paediatric compositions for treating multiple sclerosis - Google Patents

Paediatric compositions for treating multiple sclerosis

Info

Publication number
SG10201406263SA
SG10201406263SA SG10201406263SA SG10201406263SA SG10201406263SA SG 10201406263S A SG10201406263S A SG 10201406263SA SG 10201406263S A SG10201406263S A SG 10201406263SA SG 10201406263S A SG10201406263S A SG 10201406263SA SG 10201406263S A SG10201406263S A SG 10201406263SA
Authority
SG
Singapore
Prior art keywords
multiple sclerosis
treating multiple
paediatric
compositions
paediatric compositions
Prior art date
Application number
SG10201406263SA
Other languages
English (en)
Inventor
John Kovarik
Robert Schmouder
Marie-Claude Bastien
Olivier David
Goeril Karlsson
Thomas Bouillon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40974366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201406263S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG10201406263SA publication Critical patent/SG10201406263SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG10201406263SA 2008-06-20 2009-06-19 Paediatric compositions for treating multiple sclerosis SG10201406263SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13262108P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
SG10201406263SA true SG10201406263SA (en) 2015-02-27

Family

ID=40974366

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201406263SA SG10201406263SA (en) 2008-06-20 2009-06-19 Paediatric compositions for treating multiple sclerosis

Country Status (16)

Country Link
US (11) US20110152380A1 (fr)
EP (3) EP2303250A1 (fr)
JP (7) JP2011525189A (fr)
KR (4) KR20170081755A (fr)
CN (2) CN104800196A (fr)
BR (1) BRPI0914139A2 (fr)
CA (1) CA2728514C (fr)
CL (1) CL2010001463A1 (fr)
IL (2) IL209725A (fr)
MA (1) MA32480B1 (fr)
MX (1) MX2010014223A (fr)
NZ (1) NZ589618A (fr)
RU (1) RU2562571C2 (fr)
SG (1) SG10201406263SA (fr)
WO (1) WO2009155475A1 (fr)
ZA (1) ZA201008478B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170081755A (ko) 2008-06-20 2017-07-12 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
KR101393994B1 (ko) * 2008-11-11 2014-05-14 노파르티스 아게 핑골리모드 ｈｃｌ의 결정질 형태
HUE026869T2 (en) * 2008-12-22 2016-08-29 Novartis Ag Dosing regimen for fingolimod for the treatment of multiple sclerosis
SG178987A1 (en) 2009-09-29 2012-04-27 Novartis Ag Dosage regimen of an s1p receptor modulator
PE20140216A1 (es) 2011-01-07 2014-03-01 Novartis Ag Formulaciones inmunosupresoras
MX2016001422A (es) * 2013-07-29 2016-10-05 Aizant Drug Res Solutions Pvt Ltd Composicion farmaceutica de fingolimod.
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
DE122011100012I1 (de) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
JP3745772B2 (ja) 1993-12-17 2006-02-15 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤として有用なラパマイシン誘導体
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
DK0833828T3 (da) 1995-06-09 2003-03-17 Novartis Ag Rapamycinderivater
EP0937082A2 (fr) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Elements et procedes pour traiter ou prevenir les mycoses pathog nes
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
WO2000049008A1 (fr) 1999-02-20 2000-08-24 Astrazeneca Ab Derives nitriles di- et tripeptidiques, utiles en tant qu'inhibiteurs des cathepsines l et s
EP1155010A1 (fr) 1999-02-20 2001-11-21 AstraZeneca AB Derives acetamido acetonitriles en tant qu'inhibiteurs de la cathepsine l et/ou s
GB9903861D0 (en) 1999-02-20 1999-04-14 Zeneca Ltd Chemical compounds
US6395897B1 (en) 1999-03-02 2002-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5
GB9907683D0 (en) 1999-04-06 1999-05-26 Synphar Lab Inc Substituted azetidin-2-ones as cysteine protease inhibitors
EP1043027A1 (fr) * 1999-04-08 2000-10-11 Applied Research Systems ARS Holding N.V. Traitement combiné de l'esclerose multiple avec l'interferon et l'hormone de croissance
GB9911417D0 (en) 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
GB9917909D0 (en) 1999-07-31 1999-09-29 Synphar Lab Inc Cysteine protease inhibitors
ES2219388T3 (es) 1999-08-24 2004-12-01 Ariad Gene Therapeutics, Inc. 28-epi-rapalogos.
US6492362B1 (en) 1999-09-16 2002-12-10 Axys Pharmaceuticals, Inc. Compounds and compositions as cathepsin S inhibitors
GB9930449D0 (en) 1999-12-23 2000-02-16 Promotion & Display Tech Ltd Handset
CO5280088A1 (es) 2000-04-18 2003-05-30 Smithkline Beecham Corp Inhibidores de proteasa
ATE324372T1 (de) 2000-08-14 2006-05-15 Ortho Mcneil Pharm Inc Substituierte pyrazole
WO2002014315A2 (fr) 2000-08-14 2002-02-21 Ortho Mcneil Pharmaceutical, Inc. Pyrazoles substitutes
AU8125501A (en) 2000-08-14 2002-02-25 Ortho Mcneil Pharm Inc Substituted pyrazoles
US20040024000A1 (en) 2000-10-19 2004-02-05 Rajeshwar Singh Dihydropyrimidine derivatives as cysteine protease inhibitors
MXPA03005601A (es) 2000-12-22 2004-12-02 Axys Pharm Inc Nuevos compuestos y composiciones como inhibidores de catepsina.
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
US6900237B2 (en) 2001-09-14 2005-05-31 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
CN1324008C (zh) 2001-09-14 2007-07-04 安万特药物公司 作为组织蛋白酶抑制剂的新化合物和组合物
EP1434769A2 (fr) 2001-10-02 2004-07-07 Boehringer Ingelheim Pharmaceuticals Inc. Composes utiles comme inhibiteurs reversibles de cysteine protease
WO2003037892A1 (fr) 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes convenant comme inhibiteurs reversibles de proteases de la cysteine
WO2003041649A2 (fr) 2001-11-13 2003-05-22 Merck Frosst Canada & Co. Derives cyanoalkylamino utilises comme inhibiteurs de la protease
WO2003042197A1 (fr) 2001-11-14 2003-05-22 Aventis Pharmaceuticals Inc. Nouveaux composes et compositions jouant le role d'inhibiteurs de cathepsine s
EP1389480A1 (fr) * 2002-08-14 2004-02-18 Mondobiotech Interferon SA Utilisation thérapeutique de guanylhydrazones pour l'inhibition des procédés dépendant du CD83 et de la maturation des cellules dendritiques
TWI376363B (en) * 2002-09-24 2012-11-11 Novartis Ag Pharmaceutical combination for treating demyelinating disease
PE20130200A1 (es) 2003-04-08 2013-03-09 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
WO2004094653A2 (fr) * 2003-04-22 2004-11-04 Irm Llc Analyse differentielle de la longueur des marqueurs de la proliferation cellulaire
JP4861177B2 (ja) * 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
PL3103448T3 (pl) 2006-09-26 2019-12-31 Novartis Ag Kompozycje farmaceutyczne zawierające modulator S1P
KR20170081755A (ko) 2008-06-20 2017-07-12 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물

Also Published As

Publication number Publication date
EP3011958A1 (fr) 2016-04-27
CN104800196A (zh) 2015-07-29
MA32480B1 (fr) 2011-07-03
CN102076335A (zh) 2011-05-25
IL209725A (en) 2016-11-30
JP2011525189A (ja) 2011-09-15
US20130230489A1 (en) 2013-09-05
JP2023153786A (ja) 2023-10-18
RU2011101771A (ru) 2012-07-27
KR20160131126A (ko) 2016-11-15
KR20170081755A (ko) 2017-07-12
AU2009259950A1 (en) 2009-12-23
BRPI0914139A2 (pt) 2015-10-20
JP2020063269A (ja) 2020-04-23
NZ589618A (en) 2012-09-28
KR20110020928A (ko) 2011-03-03
US20210023027A1 (en) 2021-01-28
EP2303250A1 (fr) 2011-04-06
JP2018184424A (ja) 2018-11-22
JP2021152016A (ja) 2021-09-30
US20190117593A1 (en) 2019-04-25
US20180177747A1 (en) 2018-06-28
MX2010014223A (es) 2011-01-21
KR20180017232A (ko) 2018-02-20
US20160206574A1 (en) 2016-07-21
CL2010001463A1 (es) 2011-05-06
US20190358178A1 (en) 2019-11-28
JP2017122106A (ja) 2017-07-13
US20200197334A1 (en) 2020-06-25
US20170333368A1 (en) 2017-11-23
US20160022611A1 (en) 2016-01-28
IL248919B (en) 2018-12-31
IL248919A0 (en) 2017-01-31
IL209725A0 (en) 2011-02-28
CA2728514C (fr) 2020-08-11
US20170128389A1 (en) 2017-05-11
EP3545953A1 (fr) 2019-10-02
JP2015107984A (ja) 2015-06-11
US20110152380A1 (en) 2011-06-23
WO2009155475A1 (fr) 2009-12-23
ZA201008478B (en) 2012-01-25
RU2562571C2 (ru) 2015-09-10
CA2728514A1 (fr) 2009-12-23

Similar Documents

Publication Publication Date Title
IL266189A (en) Methods for treating advanced multiple sclerosis
HK1139204A1 (en) Compositions and uses for treating multiple sclerosis
EP2282719A4 (fr) Compositions et procédés pour traiter la sclérose en plaques
EP2355660A4 (fr) Compositions et procédés pour traiter une sclérose en plaques
IL248919A0 (en) Pediatric compounds for the treatment of multiple sclerosis
PT2205720T (pt) Composições para tratamento de esclerose múltipla
PL2283101T3 (pl) Kompozycje na bazie wodorofluoroolefin
PL2283102T3 (pl) Kompozycje wodorofluoroolefin
GB0808835D0 (en) Therapeutic compositions
EP2368559A4 (fr) Composition pour empêcher ou traiter l'athérosclérose
HK1154797A1 (en) Composition for treating disease
GB0819958D0 (en) Therapeutic compositions
EP2174956A4 (fr) Compositions de traitement antifibrinolitique
HK1159997A1 (en) Colostrum composition
GB0920151D0 (en) Contrast agent compositions
PL384259A1 (pl) Kompozycja farmaceutyczna do leczenia chorób skórnych
IL210519A0 (en) Anti-phthiraptera treatment compositions
GB0614058D0 (en) Treatment for multiple sclerosis
GB0722030D0 (en) Compositions for treating tumours
PL2341937T3 (pl) Kompozycja do leczenia choroby
GB0800412D0 (en) Compositions
GB0805099D0 (en) Claening compositions